A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis

por Harrison, Claire, Heidel, Florian H., Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Hayat, Amjad, Passamonti, Francesco, Conneally, Eibhlin, Kindler, Thomas, Martino, Bruno, Lipka, Daniel B., Stefanelli, Tommaso, Roussou, Pantelia, Germano, Davide, Ewan, Jacqueline, Ribrag, Vincent
Publicado 2022

Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10(9)/L to <100 × 10(9)/L) at baseline: the final analysis of EXPAND

por Guglielmelli, Paola, Kiladjian, Jean-Jacques, Vannucchi, Alessandro M., Duan, Minghui, Meng, Haitao, Pan, Ling, He, Guangsheng, Verstovsek, Srdan, Boyer, Françoise, Barraco, Fiorenza, Niederwieser, Dietger, Pungolino, Ester, Liberati, Anna Marina, Harrison, Claire, Roussou, Pantelia, Wroclawska, Monika, Karumanchi, Divyadeep, Sinclair, Karen, te Boekhorst, Peter A.W., Gisslinger, Heinz
Publicado 2022